Nervous System DiseasesNCT02443857
Feasibility of a New Pediatric Arm Rehabilitation Robot ChARMin
A study testing ChARMin in people with Nervous System Diseases, run by Huub van Hedel at 1 site in Switzerland.
Trial summary
The purpose of this study is to investigate the applicability and feasibility of the newly developed robot platform for upper extremity therapy ("ChARMin") in children undergoing neurorehabilitation. Read more about this study
- Who is it for?
- Ages 5 to 21 yearsHealthy volunteers can take part
- Conditions the study is for
- Nervous System Diseases
- What is being tested?
- ChARMin
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 63 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 Jun 2015to 30 May 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 to 21 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Who may be able to join
- Age between 5 and 21 years
- Neurological diagnoses
- Impairment of the upper extremity (for projects (i) and (ii) we might also include patients without upper extremity impairments to cover a wide range of patients with different abilities)
- Other (non-neurological) diagnoses, who require intense training of the upper extremity
Who cannot join
- Strong adipositas, which makes it not possible to adjust the cuffs and orthoses to the anthropometrics of the participant
- Fixed contractures of the upper extremity that should be positioned in ChARMin
- Instabilities of bones or joints, fractures or osteoporosis/osteopenia
- Allergy against material of cuffs
- Open skin lesions of the upper extremity that should be positioned in ChARMin
- Luxations or subluxations of joints of the upper extremity that should be positioned in ChARMin
Show all 23Show fewer
- Strong pain that increases while training in ChARMin*
- Injuries or lesioned nerves of the upper extremity that should be positioned in ChARMin*
- Strong spontaneous movements like ataxia, dyskinesia, myoclonus*
- Instable vital functions like pulmonal or cardiovascular conditions
- Implanted pace maker, defibrillator of the heart
- Implanted shunt by hydrocephalus*
- Implanted cochlear or baha*
- Uncooperative or aggressive behaviour
- Known or suspected non-compliance
- Severe cognitive deficits
- Inability to signal pain or discomfort
- Apraxia*
- Severe visual impairment (inability to see the screen)
- Severe spasticity (Ashworth 4)
- Severe epilepsy*
- Insufficient head stability
- Infections requiring isolation of the patient Contraindications marked with an * are relative contraindications. Final approval needs to be obtained from the medical doctor.
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
Rehabilitation Center for Children and Adolescents of the University Children's Hospital Zurich
Affoltern am Albis, 8910
About this study
Official title: Feasibility of a New Pediatric Arm Rehabilitation Robot ChARMin: A Monocentric Interventional Study
The purpose of this study is to investigate the applicability and feasibility of the newly developed robot platform for upper extremity therapy ("ChARMin") in children undergoing neurorehabilitation.
Read the detailed description
Background and Rationale: Children with neurological diagnoses including congenital or acquired brain lesions often have impaired upper extremity function that limits activities of daily life and independence. While several rehabilitation technologies in the clinical routines are being applied to improve upper extremity functions in these patients, the technology to train more severely affected children was not available so far. Since 3 years, the investigators are working together with the Sensory-Motor Systems Lab at ETH Zurich on a new robot platform specifically developed for upper extremity therapy in children (the 'Children's Arm Rehabilitation Mechatronic Interface' or 'ChARMin'). This group showed recently in a single blinded RCT that their adult upper extremity robot ARMin is an effective neurorehabilitation tool for adults after stroke (especially for the more severely affected patients). Now, that ChARMin is finished the investigators would like to study whether it is feasible to apply this prototype to children and adolescents undergoing neurorehabilitation.
Objective(s): As ChARMin was specifically developed for children and adolescents, the investigators first want to explore whether it is feasible to apply it to children and adolescents undergoing neurorehabilitation. Six studies will be performed with the following main objectives: (i) to investigate the applicability (technical aspects, patient-related aspects, operability/handling of the robot, the different control modes of the device, safety and the software interface) of ChARMin; (ii) to determine whether differences between game scores, kinematic and kinetic metrics provided by ChARMin, additionally applied physiological measures and adverse events differ when participants train with the free non-supported mode, the assist-as-needed mode and the fully guided mode; (iii) to determine the psychometric properties (validity, reliability and responsiveness) of the assessments integrated in ChARMin; (iv) to describe the application of the system in 30 participants and evaluate the concomitant changes in upper extremity motor function (open labelled interventional study without control group); (v) specific motor learning studies in 120 patients investigating whether children with neurological diagnoses can improve arm and hand task performance during repetitive training with ChARMin, are able to retain improved levels of task performance and how task performance is influenced by other interventions; (vi) to perform an ecological study monitoring safety, functional progress and (changes in) the application of ChARMin in 120 participants following an in- or out-patient program (comparable to subproject iv).
Outcome(s): The outcomes are in line with the objectives of each subproject. Some outcome measures are specifically performed for this study (e.g. safety, game scores, assessments integrated in ChARMin), others are clinically routinely applied measures (no additional burden for the patient). The investigators do not apply any invasive tools and assure that the amount of additional assessments will be limited to keep the burden for the participants acceptable.
Study design: Most projects are open labelled interventional studies investigating the applicability, safety and usability of a newly developed upper extremity robot ChARMin. Project (i) will investigate the feasibility of ChARMin in 30 children and adolescents. Project (ii) will be a randomized study investigating differences in the various measures between the 3 control modes of ChARMin. Project (iii) include psychometric studies where a single measurement is necessary (validity), or two repeated measurements are performed (within 3-7 days to determine reliability and between onset and end of rehabilitation to determine responsiveness). Project (v) consists of motor learning studies where a large number of repetitions are performed in a relative short time to determine changes in task performance, retention and generalizability. Projects (iv) and (vi) are open labelled interventional studies investigating the application of ChARMin and concomitant changes in upper extremity function without control group.
Measurements and procedures: Participants will be positioned in a comfortable position on a chair. After the required anthropometrics have been assessed, the ChARMin is adjusted and the cuffs of ChARMin will be fixated to the patient. Depending on the study, the participant will be informed and instructed what task/assessment or game will be made and what the goal is. Then, the participant will perform the task, while the investigator/therapist will be there to answer any questions, make sure the patient is comfortable, and to control the device, including the emergency buttons. Afterwards, the investigator/therapist will loosen the cuffs and assist if needed the participant getting out of the chair. The therapist will control the participant's skin and will ask for any other signs of discomfort. The duration of a session will remain within 45 minutes. In other sessions, clinical routine assessments will be performed.
Study Product / Intervention: The Children's Arm Rehabilitation Mechatronic Interface (ChARMin) is a newly developed upper extremity exoskeleton robot which can assist single joint movements and complex spatial reaching movements involving movements for shoulder, elbow, wrist and hand. As several subprojects are performed, the intervention could last a single training session of about 45 minutes, two or three sessions (for example to investigate reliability of assessments) or a longer training duration as prescribed by the medical doctor (e.g. for several weeks 3-5 times per week, as part of an intense a rehabilitation program).
Control Intervention (if applicable): NA (subproject 2: each child is its own control)
Number of Participants with Rationale: In general, the investigators plan to include about 30 participants per project as this number would results in a more or less normal distribution, and for psychometric studies, this is the number of participants needed to score a psychometric study of sufficient quality to be included in a best evidence synthesis.
Subproject (i): 30 participants. Subproject (ii): 30 participants. For subproject (iii) the investigators plan to recruit 60 participants (with at least 2 measurements per participant). Likely, the number might be smaller if participants agree to undergo 3 assessment sessions (first for validity, second for reliability and a final one for responsiveness). Reference values will be obtained in 40 healthy participants.
Subproject (iv): 30 participants. Subproject (v): Pilot motor learning studies will be performed in 40 participants, while the definite motor learning studies will be performed in 80 participants.
Subproject (vi): 120 participants. Please note, participants will likely contribute to more than 1 subproject with no high burden. Therefore, the total number of patients will therefore likely be smaller than 390.
Study Duration: 5 years
Study Schedule: Month Year of First-Participant-In (Mai 2015). Month Year of Last-Participant-Out (April 2020)
Study Centre(s): Monocentric study: Rehabilitation Center Affoltern am Albis
Statistical Considerations: The investigators will mainly report descriptive statistics. Normal distribution will be determined with the Shapiro-Wilk test. Comparisons between two dependent groups will be performed with Wilcoxon's or paired-t-test. Comparisons between two independent groups will be performed with a Mann-Whitney U test or a Student's t-test. Differences between three groups will be determined with a Friedman's test (dependent groups) or an ANOVA (independent groups). Relationships will be analysed with a Spearman's or Pearson correlation coefficient. Motor learning will be quantified with various measures: learning or adaptive rate will be fitted with a power or exponential regression; ratios will be calculated to quantify the transfer or retention between blocks of trials and retention.
GCP Statement: This study will be conducted in compliance with the protocol, the current version of the Declaration of Helsinki, the ICH-GCP or ISO EN 14155 (as far as applicable) as well as all national legal and regulatory requirements.
- Conditions
- Nervous System Diseases
- Being tested
- ChARMin
- Medical subject headings
- Nervous System Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ChARMinDevice
Also called ChARMin-1
The aim is to investigate the applicability (technical aspects, patient-related aspects, operability/handling of the robot, the different control modes of the device, safety and the software interface) of ChARMin.
ChARMinDevice
Also called ChARMin-2
The aim is to determine whether differences between game scores, kinematic and kinetic metrics provided by ChARMin, additionally applied physiological measures and adverse events differ when participants train with the free non-supported mode, the assist-as-needed mode and the fully guided mode.
ChARMinDevice
Also called ChARMin-3
The aim is to determine the psychometric properties (validity, reliability and responsiveness) of the assessments integrated in ChARMin.
ChARMinDevice
Also called ChARMin-4
The aim is to describe the application of the system in 30 participants and evaluate the concomitant changes in upper extremity motor function (open labelled interventional study without control group).
ChARMinDevice
Also called ChARMin-5
The aim is to perform specific motor learning studies in 120 patients investigating whether children with neurological diagnoses can improve arm and hand task performance during repetitive training with ChARMin, are able to retain improved levels of task performance and how task performance is influenced by other interventions.
ChARMinDevice
Also called ChARMin-6
The aim is to perform an ecological study monitoring safety, functional progress and (changes in) the application of ChARMin in 120 participants following an in- or out-patient program (comparable to subproject ChARMin-4).
| Study group | Role | What they receive |
|---|---|---|
| ChARMin | Experimental | Single-arm only Receives: Device: ChARMin |
What is being measured
The primary outcome is the main question the study is designed to answer.
ChARMin-1: Score on the feasibility questionnaire [points]
The feasibility questionnaire is a self-developed tool, which covers the following areas:
- Technical aspects:
- Patient-related aspects:
- Safety
- Interface/Games/Assessments
Measured: Up to 8 weeks
ChARMin-2: Game Scores [points]
To calculate the game scores of each game, several kinematic and kinetic measures are recorded and processed during the games (for instance number of collected items)
Measured: up to 24 weeks
ChARMin-3: Assessment battery integrated into the ChARMin software [points]
The assessment battery consists of:
- Range of motion
- Workspace measurement
- Quality of movement during targeted movements
- Isometric strength measurement
- Resistance to passive movement of the arm (stiffness)
- Accuracy of performing a circle movement in the frontal plane.
Measured: Up to 24 weeks
ChARMin-3: Change from baseline of the assessment battery integrated into the ChARMin software [delta points]
To assess the reliability of the assessment battery.
The assessment battery consists of:
- Range of motion
- Workspace measurement
- Quality of movement during targeted movements
- Isometric strength measurement
- Resistance to passive movement of the arm (stiffness)
- Accuracy of performing a circle movement in the frontal plane.
Measured: Twice within 3-7 days
ChARMin-3: Change from baseline of the assessment battery integrated into the ChARMin software
To assess the responsiveness of the assessment battery.
The assessment battery consists of:
- Range of motion
- Workspace measurement
- Quality of movement during targeted movements
- Isometric strength measurement
- Resistance to passive movement of the arm (stiffness)
- Accuracy of performing a circle movement in the frontal plane.
Measured: At onset and end of the hospital stay, which covers an expected average of 7 weeks
ChARMin-4 and ChARMin-6: Change from baseline in the Box and Block Test [delta of the number of blocks transferred]
Individuals are seated at a table, facing a rectangular box that is divided into two square compartments of equal dimension by means of a partition. 150, 2.5 cm, colored, wooden cubes or blocks are placed in one compartment or the other. The participant is instructed to move as many blocks as possible, one at a time, from one compartment to the other for a period of 60 seconds. To administer the test, the examiner is seated opposite the individual in order to observe test performance. The BBT is scored by counting the number of blocks carried over the partition from one compartment to the other during the one-minute trial period. Patient's hand must cross over the partition in order for a point to be given, and blocks that drop or bounce out of the second compartment onto the floor are still rewarded with a point.
Measured: At onset and end of hospital stay, which covers an expected average of 7 weeks
ChARMin-5: Game scores [points]
To calculate the game scores of each game, several kinematic and kinetic measures are recorded and processed during the games (for instance number of collected items)
Measured: up to 24 weeks
Secondary outcomes (11)
ChARMin-2: Joint angle measures provided by ChARMin [degrees]
Measured: up to 24 weeks
ChARMin-2: Force measures provided by ChARMin [Newton]
Measured: up to 24 weeks
ChARMin-2: Amplitude of muscle activation [microVolt]
Measured by surface electromyography
Measured: up to 24 weeks
ChARMin-2: Palmar skin conductance [microVolt]
Measured via sympathetic skin response as a surrogate of the parasympathetic nervous system
Measured: up to 24 weeks
ChARMin-2: Heart rate [beats per minute]
Measured via chest belt to get an idea about the cardiovascular intensity of the training.
Measured: up to 24 weeks
ChARMin-2: Adverse events [number and kind of events]
Measured: up to 24 weeks
ChARMin-2: Score on the motivational questionnaire [points]
Measured: up to 24 weeks
ChARMin-4 and ChARMin-6: Change from baseline in the score of the assessment battery integrated into the ChARMin software [delta points]
The assessment battery consists of:
- Range of motion
- Workspace measurement
- Quality of movement during targeted movements
- Isometric strength measurement
- Resistance to passive movement of the arm (stiffness)
- Accuracy of performing a circle movement in the frontal plane.
Measured: At onset and end of hospital stay, which covers an expected average of 7 weeks
ChARMin-4 and ChARMin-6: Change from baseline in the Nine-hole Peg Test [delta seconds]
Measured: At onset and end of hospital stay, which covers an expected average of 7 weeks
ChARMin-4 and ChARMin-6: Change from baseline in the brain reorganization measured by transcranial magnetic stimulation [delta milliseconds]
Transcranial magnetic stimulation to investigate whether the corticospinal tract is ipsi- or contralaterally reorganised
Measured: At onset and end of hospital stay, which covers an expected average of 7 weeks
ChARMin-4 and ChARMin-6: Change from baseline in strength of fingers and hand [delta Newton]
Measured by dynamometry.
Measured: At onset and end of hospital stay, which covers an expected average of 7 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 May 2015 (estimated)
- Study start1 Jun 2015
- Primary completion6 Jun 2024
- Study completion30 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Nervous System DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Enrolment
- 63 participants (actual)
Sponsor and investigators
- Lead sponsor
- Huub van Hedel
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Huub van Hedel, University Children's Hospital, Zurich
- Investigators
- Hubertus JA van Hedel, PhD, Principal investigator, Rehabilitation Center for Children and Adolescents of the University Children's Hospital Zurich
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02443857
- Sponsor's protocol ID
- ChARMin
- Status last verified
- Apr 2026
- First submitted
- 16 Apr 2015
- Last updated
- 7 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Graser JV, Prospero L, Liesch M, Keller U, van Hedel HJA. Test-retest reliability of upper limb robotic exoskeleton assessments in children and youths with brain lesions. Sci Rep. 2022 Oct 6;12(1):16685. doi: 10.1038/s41598-022-20588-8.
PubMed 36202825Graser JV, Bastiaenen CHG, Gut A, Keller U, van Hedel HJA. Contextual interference in children with brain lesions: a pilot study investigating blocked vs. random practice order of an upper limb robotic exergame. Pilot Feasibility Stud. 2021 Jun 25;7(1):135. doi: 10.1186/s40814-021-00866-4.
PubMed 34172085Graser JV, Bastiaenen CHG, Keller U, van Hedel HJA. Contextual interference in children with brain lesions: protocol of a pilot study investigating blocked vs. random practice order of an upper limb robotic exergame. Pilot Feasibility Stud. 2020 Oct 15;6:156. doi: 10.1186/s40814-020-00694-y. eCollection 2020.
PubMed 33072397
Study at a glance
From the registry record, last updated by the sponsor on 7 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feasibility of a New Pediatric Arm Rehabilitation Robot ChARMin: A Monocentric Interventional Study
- ClinicalTrials.gov ID
- NCT02443857
- Acronym / sponsor ID
- ChARMin
- Conditions
- Nervous System Diseases
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 63 participants (actual)
- Lead sponsor
- Huub van HedelUniversity, hospital or other
- Study start
- 1 Jun 2015 (actual)
- Primary completion
- 6 Jun 2024 (actual)
- Study completion
- 30 May 2025 (actual)
- First posted
- 14 May 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to investigate the applicability and feasibility of the newly developed robot platform for upper extremity therapy ("ChARMin") in children undergoing neurorehabilitation.
Detailed description
Background and Rationale: Children with neurological diagnoses including congenital or acquired brain lesions often have impaired upper extremity function that limits activities of daily life and independence. While several rehabilitation technologies in the clinical routines are being applied to improve upper extremity functions in these patients, the technology to train more severely affected children was not available so far. Since 3 years, the investigators are working together with the Sensory-Motor Systems Lab at ETH Zurich on a new robot platform specifically developed for upper extremity therapy in children (the 'Children's Arm Rehabilitation Mechatronic Interface' or 'ChARMin'). This group showed recently in a single blinded RCT that their adult upper extremity robot ARMin is an effective neurorehabilitation tool for adults after stroke (especially for the more severely affected patients). Now, that ChARMin is finished the investigators would like to study whether it is feasible to apply this prototype to children and adolescents undergoing neurorehabilitation.
Objective(s): As ChARMin was specifically developed for children and adolescents, the investigators first want to explore whether it is feasible to apply it to children and adolescents undergoing neurorehabilitation. Six studies will be performed with the following main objectives: (i) to investigate the applicability (technical aspects, patient-related aspects, operability/handling of the robot, the different control modes of the device, safety and the software interface) of ChARMin; (ii) to determine whether differences between game scores, kinematic and kinetic metrics provided by ChARMin, additionally applied physiological measures and adverse events differ when participants train with the free non-supported mode, the assist-as-needed mode and the fully guided mode; (iii) to determine the psychometric properties (validity, reliability and responsiveness) of the assessments integrated in ChARMin; (iv) to describe the application of the system in 30 participants and evaluate the concomitant changes in upper extremity motor function (open labelled interventional study without control group); (v) specific motor learning studies in 120 patients investigating whether children with neurological diagnoses can improve arm and hand task performance during repetitive training with ChARMin, are able to retain improved levels of task performance and how task performance is influenced by other interventions; (vi) to perform an ecological study monitoring safety, functional progress and (changes in) the application of ChARMin in 120 participants following an in- or out-patient program (comparable to subproject iv).
Outcome(s): The outcomes are in line with the objectives of each subproject. Some outcome measures are specifically performed for this study (e.g. safety, game scores, assessments integrated in ChARMin), others are clinically routinely applied measures (no additional burden for the patient). The investigators do not apply any invasive tools and assure that the amount of additional assessments will be limited to keep the burden for the participants acceptable.
Study design: Most projects are open labelled interventional studies investigating the applicability, safety and usability of a newly developed upper extremity robot ChARMin. Project (i) will investigate the feasibility of ChARMin in 30 children and adolescents. Project (ii) will be a randomized study investigating differences in the various measures between the 3 control modes of ChARMin. Project (iii) include psychometric studies where a single measurement is necessary (validity), or two repeated measurements are performed (within 3-7 days to determine reliability and between onset and end of rehabilitation to determine responsiveness). Project (v) consists of motor learning studies where a large number of repetitions are performed in a relative short time to determine changes in task performance, retention and generalizability. Projects (iv) and (vi) are open labelled interventional studies investigating the application of ChARMin and concomitant changes in upper extremity function without control group.
Measurements and procedures: Participants will be positioned in a comfortable position on a chair. After the required anthropometrics have been assessed, the ChARMin is adjusted and the cuffs of ChARMin will be fixated to the patient. Depending on the study, the participant will be informed and instructed what task/assessment or game will be made and what the goal is. Then, the participant will perform the task, while the investigator/therapist will be there to answer any questions, make sure the patient is comfortable, and to control the device, including the emergency buttons. Afterwards, the investigator/therapist will loosen the cuffs and assist if needed the participant getting out of the chair. The therapist will control the participant's skin and will ask for any other signs of discomfort. The duration of a session will remain within 45 minutes. In other sessions, clinical routine assessments will be performed.
Study Product / Intervention: The Children's Arm Rehabilitation Mechatronic Interface (ChARMin) is a newly developed upper extremity exoskeleton robot which can assist single joint movements and complex spatial reaching movements involving movements for shoulder, elbow, wrist and hand. As several subprojects are performed, the intervention could last a single training session of about 45 minutes, two or three sessions (for example to investigate reliability of assessments) or a longer training duration as prescribed by the medical doctor (e.g. for several weeks 3-5 times per week, as part of an intense a rehabilitation program).
Control Intervention (if applicable): NA (subproject 2: each child is its own control)
Number of Participants with Rationale: In general, the investigators plan to include about 30 participants per project as this number would results in a more or less normal distribution, and for psychometric studies, this is the number of participants needed to score a psychometric study of sufficient quality to be included in a best evidence synthesis.
Subproject (i): 30 participants. Subproject (ii): 30 participants. For subproject (iii) the investigators plan to recruit 60 participants (with at least 2 measurements per participant). Likely, the number might be smaller if participants agree to undergo 3 assessment sessions (first for validity, second for reliability and a final one for responsiveness). Reference values will be obtained in 40 healthy participants.
Subproject (iv): 30 participants. Subproject (v): Pilot motor learning studies will be performed in 40 participants, while the definite motor learning studies will be performed in 80 participants.
Subproject (vi): 120 participants. Please note, participants will likely contribute to more than 1 subproject with no high burden. Therefore, the total number of patients will therefore likely be smaller than 390.
Study Duration: 5 years
Study Schedule: Month Year of First-Participant-In (Mai 2015). Month Year of Last-Participant-Out (April 2020)
Study Centre(s): Monocentric study: Rehabilitation Center Affoltern am Albis
Statistical Considerations: The investigators will mainly report descriptive statistics. Normal distribution will be determined with the Shapiro-Wilk test. Comparisons between two dependent groups will be performed with Wilcoxon's or paired-t-test. Comparisons between two independent groups will be performed with a Mann-Whitney U test or a Student's t-test. Differences between three groups will be determined with a Friedman's test (dependent groups) or an ANOVA (independent groups). Relationships will be analysed with a Spearman's or Pearson correlation coefficient. Motor learning will be quantified with various measures: learning or adaptive rate will be fitted with a power or exponential regression; ratios will be calculated to quantify the transfer or retention between blocks of trials and retention.
GCP Statement: This study will be conducted in compliance with the protocol, the current version of the Declaration of Helsinki, the ICH-GCP or ISO EN 14155 (as far as applicable) as well as all national legal and regulatory requirements.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| ChARMin | Experimental | Device: ChARMinSingle-arm only |
Who may qualify
- Ages
- 5 to 21 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
Key inclusion criteria (4 listed)
- Age between 5 and 21 years
- Neurological diagnoses
- Impairment of the upper extremity (for projects (i) and (ii) we might also include patients without upper extremity impairments to cover a wide range of patients with different abilities)
- Other (non-neurological) diagnoses, who require intense training of the upper extremity
Key exclusion criteria (23 listed)
- Strong adipositas, which makes it not possible to adjust the cuffs and orthoses to the anthropometrics of the participant
- Fixed contractures of the upper extremity that should be positioned in ChARMin
- Instabilities of bones or joints, fractures or osteoporosis/osteopenia
- Allergy against material of cuffs
- Open skin lesions of the upper extremity that should be positioned in ChARMin
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ChARMinAlso: ChARMin-1The aim is to investigate the applicability (technical aspects, patient-related aspects, operability/handling of the robot, the different control modes of the device, safety and the software interface) of ChARMin. | Device | ChARMin |
| ChARMinAlso: ChARMin-2The aim is to determine whether differences between game scores, kinematic and kinetic metrics provided by ChARMin, additionally applied physiological measures and adverse events differ when participants train with the free non-supported mode, the assist-as-needed mode and the fully guided mode. | Device | ChARMin |
| ChARMinAlso: ChARMin-3The aim is to determine the psychometric properties (validity, reliability and responsiveness) of the assessments integrated in ChARMin. | Device | ChARMin |
| ChARMinAlso: ChARMin-4The aim is to describe the application of the system in 30 participants and evaluate the concomitant changes in upper extremity motor function (open labelled interventional study without control group). | Device | ChARMin |
| ChARMinAlso: ChARMin-5The aim is to perform specific motor learning studies in 120 patients investigating whether children with neurological diagnoses can improve arm and hand task performance during repetitive training with ChARMin, are able to retain improved levels of task performance and how task performance is influenced by other interventions. | Device | ChARMin |
| ChARMinAlso: ChARMin-6The aim is to perform an ecological study monitoring safety, functional progress and (changes in) the application of ChARMin in 120 participants following an in- or out-patient program (comparable to subproject ChARMin-4). | Device | ChARMin |
Primary outcome
ChARMin-1: Score on the feasibility questionnaire [points]
Time frame: Up to 8 weeks
The feasibility questionnaire is a self-developed tool, which covers the following areas: * Technical aspects: * Patient-related aspects: * Safety * Interface/Games/Assessments
ChARMin-2: Game Scores [points]
Time frame: up to 24 weeks
To calculate the game scores of each game, several kinematic and kinetic measures are recorded and processed during the games (for instance number of collected items)
ChARMin-3: Assessment battery integrated into the ChARMin software [points]
Time frame: Up to 24 weeks
The assessment battery consists of: * Range of motion * Workspace measurement * Quality of movement during targeted movements * Isometric strength measurement * Resistance to passive movement of the arm (stiffness) * Accuracy of performing a circle movement in the frontal plane.
ChARMin-3: Change from baseline of the assessment battery integrated into the ChARMin software [delta points]
Time frame: Twice within 3-7 days
To assess the reliability of the assessment battery. The assessment battery consists of: * Range of motion * Workspace measurement * Quality of movement during targeted movements * Isometric strength measurement * Resistance to passive movement of the arm (stiffness) * Accuracy of performing a circle movement in the frontal plane.
ChARMin-3: Change from baseline of the assessment battery integrated into the ChARMin software
Time frame: At onset and end of the hospital stay, which covers an expected average of 7 weeks
To assess the responsiveness of the assessment battery. The assessment battery consists of: * Range of motion * Workspace measurement * Quality of movement during targeted movements * Isometric strength measurement * Resistance to passive movement of the arm (stiffness) * Accuracy of performing a circle movement in the frontal plane.
ChARMin-4 and ChARMin-6: Change from baseline in the Box and Block Test [delta of the number of blocks transferred]
Time frame: At onset and end of hospital stay, which covers an expected average of 7 weeks
Individuals are seated at a table, facing a rectangular box that is divided into two square compartments of equal dimension by means of a partition. 150, 2.5 cm, colored, wooden cubes or blocks are placed in one compartment or the other. The participant is instructed to move as many blocks as possible, one at a time, from one compartment to the other for a period of 60 seconds. To administer the test, the examiner is seated opposite the individual in order to observe test performance. The BBT is scored by counting the number of blocks carried over the partition from one compartment to the other during the one-minute trial period. Patient's hand must cross over the partition in order for a point to be given, and blocks that drop or bounce out of the second compartment onto the floor are still rewarded with a point.
ChARMin-5: Game scores [points]
Time frame: up to 24 weeks
To calculate the game scores of each game, several kinematic and kinetic measures are recorded and processed during the games (for instance number of collected items)
11 secondary outcomes
ChARMin-2: Joint angle measures provided by ChARMin [degrees]
Time frame: up to 24 weeks
ChARMin-2: Force measures provided by ChARMin [Newton]
Time frame: up to 24 weeks
ChARMin-2: Amplitude of muscle activation [microVolt]
Time frame: up to 24 weeks
ChARMin-2: Palmar skin conductance [microVolt]
Time frame: up to 24 weeks
ChARMin-2: Heart rate [beats per minute]
Time frame: up to 24 weeks
ChARMin-2: Adverse events [number and kind of events]
Time frame: up to 24 weeks
ChARMin-2: Score on the motivational questionnaire [points]
Time frame: up to 24 weeks
ChARMin-4 and ChARMin-6: Change from baseline in the score of the assessment battery integrated into the ChARMin software [delta points]
Time frame: At onset and end of hospital stay, which covers an expected average of 7 weeks
ChARMin-4 and ChARMin-6: Change from baseline in the Nine-hole Peg Test [delta seconds]
Time frame: At onset and end of hospital stay, which covers an expected average of 7 weeks
ChARMin-4 and ChARMin-6: Change from baseline in the brain reorganization measured by transcranial magnetic stimulation [delta milliseconds]
Time frame: At onset and end of hospital stay, which covers an expected average of 7 weeks
ChARMin-4 and ChARMin-6: Change from baseline in strength of fingers and hand [delta Newton]
Time frame: At onset and end of hospital stay, which covers an expected average of 7 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 May 2026.
- Derived from this study: PubMed 36202825Graser JV, Prospero L, Liesch M, Keller U, van Hedel HJA. Test-retest reliability of upper limb robotic exoskeleton assessments in children and youths with brain lesions. Sci Rep. 2022 Oct 6;12(1):16685. doi: 10.1038/s41598-022-20588-8.
- Derived from this study: PubMed 34172085Graser JV, Bastiaenen CHG, Gut A, Keller U, van Hedel HJA. Contextual interference in children with brain lesions: a pilot study investigating blocked vs. random practice order of an upper limb robotic exergame. Pilot Feasibility Stud. 2021 Jun 25;7(1):135. doi: 10.1186/s40814-021-00866-4.
- Derived from this study: PubMed 33072397Graser JV, Bastiaenen CHG, Keller U, van Hedel HJA. Contextual interference in children with brain lesions: protocol of a pilot study investigating blocked vs. random practice order of an upper limb robotic exergame. Pilot Feasibility Stud. 2020 Oct 15;6:156. doi: 10.1186/s40814-020-00694-y. eCollection 2020.
Related trials for Nervous System Diseases
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Not yet recruiting
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Aphasia (BG-Aphasia-01)
Expressive Aphasia, Aphasia Following Cerebral Infarction
Not yet recruiting
Feasibility of a Robot-Guided Active Play Intervention for Children With Cerebral Palsy
Cerebral Palsy
Active, not recruitingPhase 3
ENDOTHELION Study Group: Effect of Bosentan in NAION Patients
Ischemic Optic Neuropathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hubertus JA van Hedel, PhD principal investigator
Rehabilitation Center for Children and Adolescents of the University Children's Hospital Zurich
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing ChARMin in people with Nervous System Diseases, run by Huub van Hedel at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
ChARMin-1: Score on the feasibility questionnaire [points] (time frame: Up to 8 weeks). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02443857, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 May 2026.